Related Experiment Video
Updated: Dec 29, 2025
07:44
A Porcine Model of Acute Autologous Pulmonary Embolism
Published on: September 6, 2024
713
Anticoagulant treatment for subsegmental pulmonary embolism
Hugo Hb Yoo1, Vania Santos Nunes-Nogueira1, Paulo J Fortes Villas Boas1
1Botucatu Medical School, São Paulo State University-UNESP, Department of Internal Medicine, Botucatu, São Paulo, Brazil, 18618-687.
The Cochrane Database of Systematic Reviews
|February 8, 2020
Summary
No studies were found to evaluate anticoagulation for subsegmental pulmonary embolism (SSPE). More research is needed to determine if anticoagulation therapy is beneficial and safe for patients with SSPE.
Area of Science:
- Cardiovascular Medicine
- Pulmonary Medicine
- Evidence-Based Medicine
Background:
- Acute pulmonary embolism (PE) is a significant cause of mortality.
- Advances in CTPA have increased diagnosis of peripheral PEs, including isolated subsegmental PE (SSPE).
- The clinical significance and optimal treatment for SSPE remain unclear, with potential for unnecessary anticoagulant risks.
Purpose of the Study:
- To assess the effectiveness and safety of anticoagulation therapy versus control in patients with isolated subsegmental pulmonary embolism (SSPE) or incidental SSPE.
Main Methods:
- A systematic review was conducted by searching multiple databases (Cochrane Vascular, CENTRAL, MEDLINE, Embase, CINAHL, AMED) and clinical trial registries.
- Included studies were randomized controlled trials comparing anticoagulation therapy to control in patients with SSPE or incidental SSPE.
- Data extraction and quality assessment were planned following Cochrane Handbook guidelines.
Main Results:
- No randomized controlled trials met the inclusion criteria for this review.
- There is a lack of evidence from high-quality studies regarding the effectiveness and safety of anticoagulation for SSPE.
Conclusions:
- Currently, there is insufficient evidence from randomized controlled trials to guide anticoagulation therapy for isolated or incidental subsegmental pulmonary embolism (SSPE).
- Further well-conducted research is essential to inform clinical practice decisions regarding anticoagulation for SSPE.
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
222
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
222
01:29Venous Thrombosis III: Interprofessional Care
228
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
228
01:27Pulmonary Embolism III: Nursing Management
257
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
257
01:29Pulmonary Embolism I: Introduction
426
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
426
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
389
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
389